Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CCXI NASDAQ:INSM NASDAQ:PTCT NASDAQ:SAGE NASDAQ:SDGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCXIChemoCentryx$51.99$51.95$14.95▼$52.00$3.71B1.221.68 million shs113 shsINSMInsmed$98.81+2.2%$82.88$60.40▼$106.83$18.70B0.92.78 million shs333,725 shsPTCTPTC Therapeutics$48.66-1.7%$48.11$29.02▼$58.38$3.84B0.5869,135 shs77,527 shsSAGESage Therapeutics$9.23+0.2%$7.66$4.62▼$13.47$577.67M0.291.31 million shs385,445 shsSDGRSchrodinger$21.10-2.8%$22.33$16.60▼$28.47$1.55B1.58916,853 shs91,909 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCXIChemoCentryx0.00%0.00%0.00%0.00%0.00%INSMInsmed+0.20%-1.87%+6.30%+40.97%+32.23%PTCTPTC Therapeutics+1.60%+1.54%-4.29%+15.22%+55.87%SAGESage Therapeutics+0.11%+0.16%+31.76%+28.63%-16.50%SDGRSchrodinger+0.14%+3.58%-16.92%-11.35%+5.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCCXIChemoCentryxN/AN/AN/AN/AN/AN/AN/AN/AINSMInsmed4.6157 of 5 stars3.54.00.04.33.81.70.6PTCTPTC Therapeutics4.3227 of 5 stars4.31.00.04.41.50.81.3SAGESage Therapeutics3.2059 of 5 stars2.02.00.04.12.31.70.6SDGRSchrodinger2.6805 of 5 stars3.42.00.00.02.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCXIChemoCentryx 0.00N/AN/AN/AINSMInsmed 3.00Buy$108.079.37% UpsidePTCTPTC Therapeutics 2.67Moderate Buy$65.0033.58% UpsideSAGESage Therapeutics 1.94Reduce$8.75-5.19% DownsideSDGRSchrodinger 2.75Moderate Buy$33.2557.61% UpsideCurrent Analyst Ratings BreakdownLatest CCXI, SDGR, SAGE, PTCT, and INSM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025INSMInsmedJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$90.00 ➝ $111.007/8/2025SAGESage TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$12.00 ➝ $9.207/3/2025SDGRSchrodingerMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$28.006/20/2025SAGESage TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$7.00 ➝ $9.006/17/2025PTCTPTC TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.006/17/2025SAGESage TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$9.00 ➝ $8.506/17/2025SAGESage TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetHold ➝ Hold$8.00 ➝ $9.006/17/2025SAGESage TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$12.006/17/2025SAGESage TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$8.00 ➝ $8.506/16/2025SAGESage TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold6/11/2025INSMInsmedThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$100.00 ➝ $112.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCXIChemoCentryx$32.22M115.14N/AN/A$4.09 per share12.71INSMInsmed$381.03M49.20N/AN/A$1.60 per share61.75PTCTPTC Therapeutics$806.78M4.78N/AN/A($14.24) per share-3.42SAGESage Therapeutics$41.24M14.01N/AN/A$7.60 per share1.21SDGRSchrodinger$207.54M7.46N/AN/A$5.78 per share3.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCXIChemoCentryx-$131.76M-$1.89N/AN/AN/A-357.01%-48.52%-30.59%N/AINSMInsmed-$913.77M-$5.95N/AN/AN/A-265.93%-446.98%-52.70%8/6/2025 (Estimated)PTCTPTC Therapeutics-$363.30M$6.517.45N/AN/A33.56%-78.56%32.11%8/6/2025 (Estimated)SAGESage Therapeutics-$400.67M-$5.80N/AN/AN/A-747.63%-68.99%-60.67%7/30/2025 (Estimated)SDGRSchrodinger-$187.12M-$2.63N/AN/AN/A-83.39%-44.74%-26.29%7/30/2025 (Estimated)Latest CCXI, SDGR, SAGE, PTCT, and INSM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025SAGESage Therapeutics-$0.96N/AN/AN/A$16.69 millionN/A7/30/2025Q2 2025SDGRSchrodinger-$0.83N/AN/AN/A$52.03 millionN/A5/8/2025Q1 2025INSMInsmed-$1.36-$1.42-$0.06-$1.42$91.63 million$92.82 million5/7/2025Q1 2025SDGRSchrodinger-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 million5/6/2025Q1 2025PTCTPTC Therapeutics$0.85$10.04+$9.19N/A$437.16 million$1.18 billion4/29/2025Q1 2025SAGESage Therapeutics-$0.99-$1.01-$0.02-$1.01$14.12 million$14.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCCXIChemoCentryxN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ASAGESage TherapeuticsN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCXIChemoCentryx0.024.544.47INSMInsmed11.385.865.44PTCTPTC TherapeuticsN/A3.893.85SAGESage TherapeuticsN/A9.139.13SDGRSchrodingerN/A3.453.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCXIChemoCentryx81.09%INSMInsmedN/APTCTPTC TherapeuticsN/ASAGESage Therapeutics99.22%SDGRSchrodinger79.05%Insider OwnershipCompanyInsider OwnershipCCXIChemoCentryx8.30%INSMInsmed3.00%PTCTPTC Therapeutics5.50%SAGESage Therapeutics5.50%SDGRSchrodinger8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCXIChemoCentryx17871.36 million65.43 millionOptionableINSMInsmed1,271189.71 million184.02 millionOptionablePTCTPTC Therapeutics1,41079.26 million74.90 millionOptionableSAGESage Therapeutics69062.62 million59.18 millionOptionableSDGRSchrodinger79073.38 million67.07 millionOptionableCCXI, SDGR, SAGE, PTCT, and INSM HeadlinesRecent News About These CompaniesMorgan Stanley Assumes Coverage on Schrödinger (SDGR) StockJuly 10 at 2:16 AM | finance.yahoo.comAllspring Global Investments Holdings LLC Boosts Holdings in Schrodinger, Inc. (NASDAQ:SDGR)July 7, 2025 | marketbeat.comSDGR - Schrodinger Inc Ordinary Shares Financials - MorningstarJuly 5, 2025 | morningstar.comMMS initiates coverage on AI Biotechs, flags key pipeline catalystsJuly 3, 2025 | investing.comSchrödinger (SDGR) Receives FDA Fast Track Designation for Cancer Drug SGR-1505July 3, 2025 | msn.comMorgan Stanley Initiates Coverage on Schrodinger (NASDAQ:SDGR)July 3, 2025 | marketbeat.comSchrödinger, Inc. (SDGR) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJuly 2, 2025 | prnewswire.comShort SDGR: Schrödinger bounces from 2024 midpoint, trading range low as potential short-term targetJuly 1, 2025 | invezz.comISumitomo Mitsui Trust Group Inc. Sells 48,103 Shares of Schrodinger, Inc. (NASDAQ:SDGR)July 1, 2025 | marketbeat.comSchrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström MacroglobulinemiaJune 27, 2025 | tmcnet.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJune 23, 2025 | globenewswire.com17,493 Shares in Schrodinger, Inc. (NASDAQ:SDGR) Bought by Palumbo Wealth Management LLCJune 23, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJune 22, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJune 18, 2025 | globenewswire.comSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 17, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJune 16, 2025 | accessnewswire.comAGAMMA Investing LLC Acquires 117,796 Shares of Schrödinger, Inc. (NASDAQ:SDGR)June 14, 2025 | marketbeat.comSchrödinger: Assessing The Signal And The Noise In The Phase 1 ResultsJune 13, 2025 | seekingalpha.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGRJune 13, 2025 | accessnewswire.comAStanley Laman Group Ltd. Acquires 27,511 Shares of Schrödinger, Inc. (NASDAQ:SDGR)June 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCCXI, SDGR, SAGE, PTCT, and INSM Company DescriptionsChemoCentryx NASDAQ:CCXIChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.Insmed NASDAQ:INSM$98.81 +2.15 (+2.22%) As of 10:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.PTC Therapeutics NASDAQ:PTCT$48.66 -0.86 (-1.74%) As of 10:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Sage Therapeutics NASDAQ:SAGE$9.22 +0.02 (+0.16%) As of 10:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Schrodinger NASDAQ:SDGR$21.10 -0.61 (-2.83%) As of 10:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.